Cytosorbents (CTSO) Short term Debt (2016 - 2026)

Cytosorbents (CTSO) reported Short term Debt of $6.6 million for Q1 2026, up 165.84% quarter-over-quarter from $2.5 million in Q1 2024.

Cytosorbents (CTSO) Short term Debt (2016 - 2026) Analysis & Trends

Cytosorbents has reported Short term Debt for 8 years, with the latest figure at $6.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (changed N/A YoY), and the FY2023 full-year result was $2.5 million, changed N/A from the prior year.
  • Short term Debt for Q1 2026 stood at $6.6 million, up from $2.5 million in the prior quarter.
  • The five-year high for Short term Debt was $6.6 million in Q1 2026, with the low at $833333.0 in Q3 2023.
  • Historically, Short term Debt has averaged $3.1 million across 3 years, with a median of $2.5 million in 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Cytosorbents 28.80 Mn 24.00 Mn 6.13 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.65 Mn
Mar 31, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
Sep 30, 2023 833,333.00
Sep 30, 2020 9.17 Mn
Jun 30, 2020 6.67 Mn
Mar 31, 2020 4.17 Mn
Dec 31, 2019 1.67 Mn
Sep 30, 2019 3.13 Mn
Jun 30, 2019 833,333.00
Mar 31, 2019 1.67 Mn
Dec 31, 2018 666,667.00
Dec 31, 2017 4.00 Mn
Sep 30, 2017 3.00 Mn
Jun 30, 2017 2.00 Mn
Mar 31, 2017 1.25 Mn
Dec 31, 2016 833,333.00
Sep 30, 2016 416,667.00